Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Abroad (travel likely)RecruitingPHASE1

Conditions

Recurrent Acute Lymphoblastic Leukemia · Recurrent B Acute Lymphoblastic Leukemia · Recurrent B-Cell Prolymphocytic Leukemia · Recurrent Chronic Lymphocytic Leukemia · Recurrent High Grade B-Cell Lymphoma · Recurrent Indolent Non-Hodgkin Lymphoma · Recurrent Non-Hodgkin Lymphoma · Recurrent Transformed Chronic Lymphocytic Leukemia · Refractory Acute Lymphoblastic Leukemia · Refractory B Acute Lymphoblastic Leukemia · Refractory B-Cell Prolymphocytic Leukemia · Refractory Chronic Lymphocytic Leukemia · Refractory High Grade B-Cell Lymphoma · Refractory Indolent Non-Hodgkin Lymphoma · Refractory Non-Hodgkin Lymphoma · Refractory Transformed Chronic Lymphocytic Leukemia · Refactory Childhood Acute Lymphoblastic Leukemia · Refractory Childhood Non-Hodgkin Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
Study leads
  • Sumithira Vasu, MD

    Principal Investigator

    Ohio State University Comprehensive Cancer Center